Brief: Destiny Pharma On Track To Achieve Strategic Targets For Xf-73 Nasal And Ntcd-M3
27/05/2022 12:10
May 27 (Reuters) - Destiny Pharma PLC DEST.L :
* DESTINY PHARMA PLC - ON TRACK TO ACHIEVE OUR KEY STRATEGIC
TARGETS FOR OUR TWO LEAD PROGRAMMES, XF-73 NASAL AND NTCD-M3
* DESTINY PHARMA PLC - ACTIVE DISCUSSIONS REGARDING
OUT-LICENSING
OF OUR LEAD ASSET NTCD-M3 ARE PROGRESSING WELL.
Source text for Eikon: ID:nRSa1066Na
Further company coverage: DEST.L
((Reuters.Briefs@thomsonreuters.com;;))